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Abstract 
The onset of diabetic retinopathy is characterized by morphologic alterations of the microvessels, with thickening of the 
basement membrane, loss of inter-endothelial tight junctions and early and selective loss of pericytes, together with 
increased vascular permeability, capillary occlusions, microaneurysms and, later, loss of endothelial cells. A key role in 
the evolution of the disease is played by pericytes, specialized contractile mesenchymal cells of mesodermal origin, 
that, in capillaries, exert a function similar to smooth muscle cells in larger vessels, regulating vascular tone and 
perfusion pressure. Thickening of the basement membrane, together with systemic and local hypertension, 
hyperglycaemia, advanced glycation end-product formation and hypoxia, may disrupt the tight link between pericytes 
and EC causing pericyte apoptosis, while endothelium, deprived of proliferation control, can give rise to new vessels. 
Pericyte dropout has great consequences on capillary remodelling and may cause the first abnormalities of the diabetic 
eye which can be observed clinically. Hyperglycaemia and local hypertension are known to be a direct cause of pericyte 
apoptosis and dropout, and intracellular biochemical pathways of the glucose metabolites have been explored. However, 
the exact mechanisms are not yet fully understood and need further clarification in order to develop new effective drugs 
for the prevention of retinopathy.  
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Introduction 
Generalized increase of capillary blood flow and vasodilatation are among the first features observed at onset of 
diabetes. Subsequently, morphologic alterations of the microvessels are described, especially in the retinal district, 
where the early phases of diabetic retinopathy (DR) are characterized by thickening of the basement membrane, loss of 
inter-endothelial tight junctions and early and selective loss of pericytes, together with increased vascular permeability, 
capillary occlusions, microaneurysms and, later, loss of endothelial cells (EC) [1, 2]. Endothelium plays a complex role 
in the regulation of the vessel tone, the maintenance of the coagulation balance and the modulation of platelet 
activation. It also regulates the metabolism of the basement membrane, vascular permeability, migration of leucocytes 
and macromolecules from the vessel lumen to the sub-endothelium and vice versa [3, 4].  
However, a key role in the evolution of this complication of diabetes is played by the other capillary cell type, the 
pericyte, a specialized contractile mesenchymal cell of mesodermal origin which exerts in capillaries a function similar 
to that of smooth muscle cells (SMC) in larger vessels, regulating vascular tone and perfusion pressure [5]. Retinal 
capillary vessels are composed of a 1:1 ratio of EC and pericytes, the highest in the whole body [6], with pericytes 
closely linked to EC through gap-junctions [7] and playing a role in the regulation of their proliferation, while 
receiving nourishment and growth factors from them [5]. Thickening of the basement membrane during the first phases 
of DR, together with systemic and local hypertension, hyperglycaemia, advanced glycation end-product (AGE) 
formation and hypoxia may all disrupt this link and cause pericyte apoptosis and drop-out, while endothelium, deprived 
of proliferation control, can initiate to proliferate in microaneurysms in the early phases and, eventually, new vessels in 
later stages of retinopathy [6]. Pericyte dropout has great consequences on capillary remodelling and may cause the 
first abnormalities of the diabetic eye which can be observed clinically. 
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The pericyte: morphology and function 
Pericytes are ubiquitous, pluripotent, mesenchymal cells which derive from the neural crest during the embryonic 
development [8] and mediate physiological and pathological repair processes [9]. They were first described by Rouget 
in 1873 [10] and named by Zimmerman in 1923 [11]. Cogan and Kubawara in 1961 [12, 13] for the first time 
associated them with diabetic retinopathy.  
Pericytes have several similarities with SMC, first of all their contractile properties, and share with them common 
markers (α-smooth muscle actin and desmin) [14]. Other markers commonly used to identify these cells are the 
proteoglycan NG2 and PDGF-Rβ [15]; however, it has been demonstrated that none of them is able to recognize 
pericytes at all stages and in all contexts [5].  
A common precursor for pericytes and SMC in the development of the retina has been identified in a mural precursor 
cell type, positive for desmin and NG2 (a marker for both immature smooth muscle cells and pericytes) and present on 
undifferentiated vessels. After birth, this cell type differentiates to pericytes or SMC [16]. Possible derivation of 
pericytes from a trans-differentiation of EC to repair vessel wounds [17] and/or from bone marrow to support adult 
angiogenesis [18] has been also postulated. Several studies have underlined a strict relationship between mesenchymal 
stem cells (MSC) and pericytes. In fact, pericytes in their tissue of origin natively express the MSC markers CD44, 
CD90, CD73 and CD105 [19, 20]; cells expressing MSC markers, express also pericyte ones (α-smooth muscle actin, 
NG2 and PDGF-Rβ) [21] and pericyte clones have osteogenic, chondrogenic, adipocytic and myogenic properties, 
characteristic of MSC [22]. Moreover, bone marrow-derived MSC injected in rats with glioblastoma migrate around 
the vessels and differentiate into pericytes, as demonstrated by phenotype expression of the typical pericyte markers, 
and not EC ones [23].  
Pericytes are present in the capillaries of all districts in the body with a role of support of the microvasculature. 
However, their density is rather variable, ranging from 1:100 (pericyte:EC) in the cardiac and skeletal muscle to 1:1 in 
the retina [24]. The reason for this high ratio is the need for an extremely high barrier function in the retina itself, to 
preserve it from extra fluid deposition that could lead to visual loss [25]. Pericytes have a prominent nucleus and long 
cytoplasmic processes, some of which embrace the vessel wall while others run parallel to the axis of the capillary 
itself or protrude to reach other capillaries [25]; these processes mediate pericyte-pericyte, pericyte-EC and pericyte-
retinal neuroglia cell-to-cell communications [15]. In the retina, pericytes live in pockets embedded within the 
basement membrane (intramural pericytes) [26] and participate to its anabolism by producing glycoproteins (especially 
collagen) and glycosaminoglycans [27]; they surround the ECs which form the capillary tube and stabilize the vessel. 
The contractile phenotype of pericytes, in addition to the presence of contractile proteins (smooth muscle and non-
smooth muscle isoforms of actin and myosin), is confirmed by their response to a series of paracrine molecules which 
regulate their contractility, both vasoconstrictors, such as angiotensin II, endothelin-1, α2-adrenergic agonists, and 
vasodilators, such as NO and β2-adrenergic agonists [28]. In the brain and the retina pericyte contractility is induced by 
a rise in extracellular Ca2+ concentrations and the signal can sometimes propagate to reach distant pericytes [29]; on the 
other hand, it is demonstrated that calcium-activated intracellular cascades play key roles in the different steps of 
angiogenesis [30]. 
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Pericyte-endothelial cell interactions 
Pericytes are closely linked to EC through tight junctions, gap junctions, adhesion plaques, and peg and socket contacts 
[31] with continuous exchange of nucleotides and small molecules [32]. Interactions between the two cell types are 
also mediated by cell adhesion molecules secreted by both, whose imbalance may cause leakage of the blood barrier 
during the early phases of DR [15]. Tight junction proteins (such as claudins and occludins), interconnecting pericytes 
and EC, are structural components of the blood-retinal barrier [33] while it is through the gap junctions, membrane 
channels directly connecting the cytoplasms of the two cell types, that pericytes exert a key role in the regulation of EC 
proliferation during physiological angiogenesis [34]. Adhesion plaques, rich in fibronectin, are responsible for the 
anchorage of the pericyte to the endothelium during contraction or propagation of the shear stress [35]. 
Pericyte coverage is required for the stabilization of immature endothelial tubes [36], and vascular endothelial growth 
factor (VEGF), angiopoietin-2 (Ang-2), Transforming Growth Factor-β (TGF-β), PDGF-B and metalloproteinases are 
among the required factors for the survival and/or recruitment and differentiation of pericytes. In particular, PDGF-B, 
secreted by endothelium, and its receptor PDGFR-β (expressed in pericytes only) [37] are important in the 
proliferation, migration and recruitment of pericytes to the vasculature during retinal development and in the 
stabilization of newly-formed vessels [38, 39]. Pericyte-produced VEGF stimulates EC proliferation, and the 
interaction EC-pericyte is responsible for the activation of TGF-β, which induces the differentiation of pericytes, while 
inhibiting EC proliferation and migration, thanks to its involvement in the interactions between microvascular cells and 
ECM [15]. Angiopoietin-1 is secreted by pericytes and acts on ECs through its receptor Tie2, stabilizing vessels and 
reducing permeability, while, in contrast, Ang-2 increases permeability. On the other hand, it has been shown that Ang-
2 in combination with VEGF induces angiogenesis while, in the absence of VEGF, it causes vessel regression [40]. 
The proliferation control exerted by pericytes on EC is mediated by soluble factors able to upregulate endothelin-1 and 
downregulate iNOS production [41]. 
Besides endothelium, pericytes is also in contact with Müller cells, the main retinal glial cells, which contribute to the 
stability of the blood-retinal barrier and the maintenance of retinal homeostasis. Müller cells have been shown to 
protect both neurons and pericytes from damage caused by hyperglycaemia-induced reactive oxygen species (ROS) 
(see below) [42]. 
 
Pericyte loss during DR: evidences and clinical consequences  
Early pericyte loss is a recognized hallmark of DR [13]. The so-called “pericyte ghosts”, empty pockets within the 
basement membrane of a viable capillary formerly occupied by the pericytes themselves, a common feature of the early 
phases of the disease, are characteristic of the retina while they are rare or absent in the capillaries of the optic nerve 
and cerebral cortex [43]. Together with later loss of EC, pericyte disappearance provokes the formation of acellular 
capillaries (i.e. tubes formed by basement membrane only), capillary occlusion and formation of microaneurysms, the 
first clinically relevant lesion in the diabetic eye. Progressive vessel occlusion is followed by increased permeability, 
partly due to VEGF over-expression [44], which also induces intravessel EC proliferation and, eventually, 
neovascolarization, with consequent hemorrhages and visual loss [45] (Fig. 1). 
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Although pericyte disappearance in the first phases of DR is widely understood to be the result of direct 
hyperglycaemic damage, the exact mechanisms underlying their degeneration are still unclear. High glucose levels, in 
vitro as well as in vivo, induce pericyte apoptosis [46-50], leading to the well-known alterations of retinal capillaries. 
In particular, human retinal pericytes (HRP) are highly-susceptible to fluctuating glucose levels, rather than stable 
exposure to high glucose conditions [51, 52]. Intermittent exposure to high glucose has been described to increase 
apoptosis related to oxidative stress also in EC [53-56] and a ROS - mediated cell “memory” of vascular stress after 
glucose normalization has been shown in human EC and in the human retinal pigment epithelial cell line, ARPE-19 
[56]. These findings are consistent with the clinical observation that daily fluctuations in plasma glucose 
concentrations, such as they occur in diabetic patients, are correlated to increased risk of  cardiovascular disease [57] 
and microvascular complications [58]. Hyperglycaemia impairs retinal vessel autoregulation in humans [59], therefore 
pericytes are likely to be exposed to an increased mechanical insult secondary to systemic and capillary hypertension. 
Contraction and relaxation of pericytes is thought to regulate the luminal diameter of retinal capillaries and these cells 
are believed to play a major role in adjusting blood flow through the retinal capillary bed [60], as described above: the 
contractile phenotype of pericytes is thus an important determinant of the haemodynamic stress experienced by retinal 
capillaries. It has been showed that mechanical stretch, alone or combined with high glucose, reduces cell proliferation, 
increases apoptosis and induces morphological changes in the pericyte cytoskeleton [61]. 
Autoregulation of the vessel tone is impaired from the first phases of diabetes due to hyperglycaemia, with different 
haemodynamic alterations characteristics of the evolution of the disease. Initially, the blood flow increases in several 
vascular districts, particularly in the retina [62] and glomerulus, due to a strict correlation between the arteriolar 
vasodilatation and the high blood glucose concentrations [63]. In a second phase, endothelium seems to lose its ability 
Fig. 1. Mechanisms and consequences of pericyte loss in the pathogenesis 
of diabetic retinopathy. 
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to induce vasodilatation, due to impaired balance between vasoconstrictors, such as endothelin-1, and vasodilators, 
such as NO, the concentrations of which are reduced [64]. 
Reduced adhesion and increased apoptosis in pericytes seeded on extracellular matrix (ECM) produced by EC cultured 
in high glucose concentrations, possibly due to glycation of the matrix proteins, have been described [51, 65, 66]. Since 
the ultrastructural analysis of retinal microaneurysms shows the absence of pericytes, impaired vessel integrity after 
pericyte loss could make the capillary wall more susceptible to dilatation, leading to microaneurysms; moreover, the 
correlation between pericyte absence and retinal neovascolarization may indirectly confirm the role of pericytes in the 
inhibition of the capillary growth [6, 35, 67]. The impaired cell-to-cell and cell-to-ECM interactions are also due to 
alterations to the molecules mediating these contacts: thickening of the basement membrane derives from a process 
involving hyperglycemia-induced excess synthesis of components of the basement membrane itself, such as 
fibronectin, collagen type IV and laminin [68, 69], together with increased integrin expression [70]. In contrast with 
what happens with pericytes, increased integrin expression and fibronectin production seem to correlate with greater 
EC/ECM adhesion [71, 72]. This may negatively influence EC proliferation through the induction of cytoskeleton 
modifications [73] in the later phases of DR. Recently, it has been suggested that a long-term strategy based upon small 
interference RNA (RNA sequences which interferes with the expression of specific genes through complementary 
nucleotide sequence) may regulate fibronectin overexpression and improve vascular lesions in retinas of diabetic rats 
[74]. 
Capillary occlusion is probably caused by the complex of the alterations above mentioned: increased vascular tone, 
thickening of the basement membrane, loss of pericytes and EC with formation of acellular capillaries and obstruction 
of the vessel lumen, due to leucocyte adhesion and platelet aggregation. Ischemia and hypoxia resulting from capillary 
occlusion lead to an angiogenic response to compensate for the reduction of the blood flow downstream of the 
occlusion [75]. 
As described above, pericyte coverage is essential for the stabilization of immature endothelial tubes. PDGF-B and 
PDGFR-β are important in the proliferation, migration and recruitment of pericytes to the vasculature during retinal 
development and in the stabilization of newly-formed vessels [38, 39] and seem to play a key role in the mechanisms 
underlying vascular changes in DR [15]. Pericytes, but not endothelial cells, express PDGFR-β in vivo [37, 38]. In 
diabetic mouse retinas, PDGF-B mRNA is decreased in comparison with non-diabetic mice, suggesting a role for 
PDGF-B in hyperglycaemia-induced pericyte loss [37]. Retinas of mice with endothelium-restricted ablation of PDGF-
B showed that up to 50% pericyte loss is accompanied by vasoregression, while pericyte reduction exceeding 50% 
induces retinal vasoproliferation mimicking PDR [37, 38]. 
 
Pericyte loss during DR: the renin-angiotensin system 
The severity of vascular complications in diabetes has been associated not only with the duration and degree of 
hyperglycaemia, but also with those of hypertension [76, 77] (Fig. 1).  
The renin-angiotensin system (RAS), an endocrine system that, at a systemic level, regulate blood pression and 
electrolyte homeostasis, some twenty years ago has been described to be present also locally, with differences among 
the various tissues [78]. In particular, local RAS are present in the organs mainly affected by diabetes, such as kidney, 
peripheral nerves and the eye [79]. All components of the RAS system have been described in the neural retina, as well 
as in the capillaries [80]. In diabetes, RAS is upregulated, hyperglycemia increasing the transcription of 
angiotensinogen and the production of angiotensin II, the most important end-product of the RAS system, which binds 
to both angiotensin type 1 (AT1R) and type 2 receptors (AT2R) [81]. 
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In the eye, RAS contributes to the diabetes-induced damage through two different mechanisms: the over-activation of 
AT1R by high levels of angiotensin II increases VEGF expression in pericytes, leading to vascular leakage [82], 
pericyte-mediated vasoconstriction [83], oxidative stress [84], thickening of the basement membrane [85] and NF-κB 
activation [86]. Moreover, RAS has been described to play a role in several of the biochemical dysfunctions described 
in the following paragraph, which are directly induced by hyperglycaemia: angiotensin II increases AGE formation 
[87], protein kinase C (PKC) synthesis [88] and ROS production [82], and enhances the flux through the polyol 
pathway [89], while hyperglycaemia induces angiotensinogen gene expression through the hexosamine pathway [90]. 
There is evidence to indicate that blockade of RAS confers retinal protection in experimental models of DR and 
ischemic retinopathy, ameliorating retinal hyperpermeability [91] and restoring blood flow [92]. Recently, it has been 
demonstrated that the angiotensin converting enzyme (ACE) inhibitor captopril can block capillary degeneration in the 
early stages of DR, inhibiting hyperglycemia-induced acellular capillary formation and pericyte ghosts [93]. At a 
clinical level, blockade of the RAS, through the ACE inhibitor lisinopril, has been shown to reduce both incidence and 
progression of DR in type 1 diabetes [94], while results from the DIabetic Retinopathy Candesartan Trials (DIRECT) 
show that the AT1R blocker candesartan during a 4 year trial was able to reduce the incidence of retinopathy in patients 
with type 1 diabetes [95] and determine a regression of DR in type 2 diabetic patients [96].  
 
Pericyte loss during DR: glucose metabolism pathways 
Chronic hyperglycaemia and daily fluctuations in blood glucose have been clearly associated to the severity of 
microvascular complications and it is widely acknowledged that pericyte loss in the first phases of DR is the result of 
direct hyperglycaemic damage.  
It is possible to discriminate between two different types of mechanisms involved in glucose-mediated damage: while 
the former induces acute but reversible metabolic changes, the latter causes a cumulative damage that sometimes even 
worsens if glycaemia is rapidly restored to physiological levels [97].  
Vascular cells have been widely reported to be sensible to direct exposure to high glucose concentrations [49, 98, 99], 
their increased apoptosis being correlated to increased expression of the pro-apoptotic Bax proteins in vivo and in vitro 
[99] and activation of NF-κB in vitro [48]. However, as already mentioned, human retinal pericytes seem to be more 
sensible to intermittent than stable high glucose concentrations, due to impairment in the Bcl-2/Bax ratio [51, 52], 
while rapid glucose normalization, explained as “ROS – mediated cellular memory” of vascular stress has been shown 
in EC and retinal ARPE-19 [56], consistently with the clinical observation that daily fluctuations in plasma glucose 
concentrations in diabetic patients are related to increased risk of cardiovascular disease [57] and microvascular 
complications [58]. DR itself has been seen to accelerate after restoration of physiological glycaemic levels, mostly if 
glycaemic control is rapidly achieved [100-103]. 
A possible explanation to hyperglycaemic damage to microvascular cells, and pericytes in particular, is the 
involvement of four major biochemical pathways: 1. increased flux through the polyol pathway; 2. increased formation 
of advanced glycation end-products (AGE); 3. activation of the protein kinase C; 4. increased flux through the 
hexosamine pathway [15, 104].  
1. Aldose-reductase, the key-enzyme of the polyol pathway, reduces toxic aldehydes to inactive alcohols in 
physiological conditions. However, in the case of excess intracellular glucose, aldose-reductase converts it to 
sorbitol, consuming NADPH and giving rise to a sort of hyperglycaemic pseudohypoxia [105], together with an 
increased susceptibility to intracellular oxidative stress [106, 107]. 
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2. Excess intracellular glucose is able to react with proteins, amino acids and nucleic acids via Schiff base 
condensation, this initial reaction being followed by irreversible rearrangement into an Amadori product. AGE 
may be produced ex-novo by a slower Maillard reaction or directly derive from these early products through 
glycoxidation reactions or reactive dicarbonyl fragments generated from free glucose [108]. AGE are toxic 
products which can modify intracellular proteins, including those involved in the regulation of gene transcription 
[109], or diffuse outside the cell modifying the extracellular matrix [110], with consequent reduction of the cell-to-
cell adhesion and vascular dysfunction [65, 66], and also modify circulating blood proteins, inducing production of 
inflammatory cytokines and growth factors [111, 112].  
3. High glucose concentrations inside the cell also activate PKC synthesis through de novo synthesis of the lipid 
second messenger diacylglycerol (DAG) [113]. This may lead to decreased synthesis of endothelial nitric oxide 
synthase (eNOS), increased synthesis of endothelin-1, TGF-ß, plasminogen activator inhibitor-1 [114] and NF-κB 
[115]. 
4. Finally, high availability of intracellular glucose leads to an excess of fructose-6-phosphate which is transformed 
to glucosamine-6-phosphate and then UDP N-acetyl-glucosamine; the latter acts on serine and threonine residues 
of transcription factors, giving rise to pathological changes in gene expression [116, 117]. 
A common denominator of these apparently independent biochemical pathways, the so-called “unifying mechanism”, 
was identified by Brownlee and co-workers in excess ROS production by the mitochondria, induced by high glucose as 
a result of increased flux through the Krebs’ cycle [115]. ROS would activate the poly-(ADP-ribose)-polymerase 
(PARP), which in turn inhibits glyceraldehyde-phosphate-dehydrogenase (GAPDH) activity [118], therefore pushing 
metabolites from glycolysis in the upstream pathways mentioned above. 
Evidence in the literature shows that oxidative stress, implicated in pericyte loss, may be induced also by extravasated, 
modified plasma LDL, present in the diabetic but not the healthy retina [119, 120]. 
 
New hypothesis for pericyte loss involvement in the pathogenesis of DR 
Recent findings hypothesize that some pericytes, having lost contact with their original capillaries, do not undergo 
apoptosis, but migrate to other capillaries or into the perivascular space. Ang-2 overexpression, induced by excess AGE 
in the hyperglycaemic milieu, may play a key role in this process, since Ang-2 deficient mice did not show any 
migration in the presence of hyperglycaemia [121]. 
High glucose was reported to induce mitochondrial fragmentation and dysfunction in retinal endothelial cells, 
contributing to apoptosis. Recently, it has been demonstrated that, in hyperglycaemic-like conditions, mitochondria of 
retinal pericytes also show fragmentation, metabolic dysfunction and reduced extracellular acidification [122]. 
It has also been suggested that pericyte are immunosuppressive and protect EC from inflammation-mediated apoptosis. 
Hyperglycemic conditions may impair their T cell inhibitory activity, favouring retinal inflammation and contributing to 
the pathogenesis of DR [123]. 
Another recent work verified the hypothesis that auto-antibodies against pericytes could develop in DR, inducing retinal 
pericyte dysfunction or eventually death through complement activation [124]. 
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Conclusions 
Early pericyte dropout and apoptosis are among the earliest events in the natural history of diabetic retinopathy. 
Hyperglycaemia and hypertension have been correlated to this disappearance but the exact mechanisms are not yet fully 
understood. Thickening of the basement membrane, also occurring in the first phases of retinopathy, may contribute to 
disrupt the tight connections between pericytes and endothelial cells, impairing their reciprocal, fine-controlled balance. 
Without the proliferation control exerted by pericytes, EC are free to duplicate, giving rise to angiogenesis and leading 
to the advanced phases of diabetic retinopathy.  
Despite advancements in ophthalmic care and management of both type 1 and type 2 diabetes, proliferative diabetic 
retinopathy and diabetic macular oedema remain leading causes of blindness, for which at the moment there are no 
specific forms of prevention, apart from the day to day struggle of keeping blood glucose and pressure under optimal 
control. Even so, the onset and progression of retinopathy are delayed but not entirely prevented. Therefore, there is a 
need for alternative, low cost pharmacologic approaches which should be addressed towards the mechanisms presiding 
over of the first key events of the disease, and pericyte loss may well be an important one. 
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